Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.37 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776212 | 0.89 | NOTUM (0.39) | NOTUMKDM4EIRAK4MAOAMAOB | |
| SCHEMBL16776144 | 0.81 | KMT2A (0.44) | CA9CNR1RPS6KA2ALDH1A1CREBBP | |
| SCHEMBL16776011 | 0.79 | CA9 (0.38) | CA9RPS6KA3CNR1RPS6KA2ALDH1A1 | |
| SCHEMBL16776146 | 0.79 | HTR2C (0.48) | ALDH1A1 | |
| SCHEMBL16776024 | 0.78 | IMPDH2 (0.46) | CA9RPS6KA3CNR1RPS6KA2ALDH1A1 | |
| SCHEMBL16775911 | 0.77 | RPS6KA3 (0.43) | RPS6KA3CNR1RPS6KA2 | |
| SCHEMBL16776318 | 0.77 | AURKA (0.38) | KDM4ECA9RPS6KA2ALDH1A1RAB9A | |
| SCHEMBL16776022 | 0.77 | RPS6KA2 (0.41) | CA9RPS6KA2 | |
| SCHEMBL16776313 | 0.77 | NAMPT (0.40) | CNR1ALDH1A1CREBBPRAB9A | |
| SCHEMBL16776311 | 0.77 | MAOA (0.39) | NOTUMCA9MAOAMAOBRPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | NOTUM 3260/4885KDM4E 950/4885CA9 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.